StockNews.AI
ELUT
StockNews.AI
139 days

Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes

1. Elutia introduces EluPro™ for cardiac devices at HRS 2025. 2. EluPro aims to reduce bacterial colonization in CIEDs. 3. Physicians can experience EluPro's soft, conforming biomatrix. 4. EluPro combines performance with trusted dual-antibiotic technology. 5. Elutia focuses on enhancing compatibility between devices and patients.

9m saved
Insight
Article

FAQ

Why Bullish?

The introduction of EluPro suggests a significant advancement in their technology pipeline, similar to other successful product launches in the medical devices sector which often lead to stock price increases. Historical examples include similar announcements from companies like Medtronic, which saw stock appreciation following innovative product launches.

How important is it?

The article highlights a significant product introduction that addresses clinical needs, potentially driving revenue and positioning Elutia favorably against competitors. The strong emphasis on innovation and physician engagement indicates substantial market potential.

Why Short Term?

The upcoming Heart Rhythm Society event creates immediate attention and potential sales discussions, likely impacting stock performance quickly. Similar industry events have historically resulted in short-term price rallies post-announcement.

Related Companies

MDTSYKABT
April 02, 2025 16:05 ET  | Source: Elutia Inc. Introduction of EluPro at Heart Rhythm 2025 in San Diego, April 25-27, 2025 SILVER SPRING, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, is proud to announce the debut of its EluPro™ Antibiotic-Eluting BioEnvelope designed for cardiac implantable electronic devices (CIEDs) and neurostimulators at the Heart Rhythm Society’s annual meeting (HRS 2025). Attendees will have the opportunity to experience firsthand the soft, conforming feel of EluPro and discover how its natural biomatrix supports healing while delivering trusted antibiotics to reduce bacterial colonization. Engineered for both performance and handling, EluPro features a proprietary biomatrix that drapes naturally around CIEDs, avoiding the rough, stiff feel often associated with synthetic alternatives. Combined with a trusted dual-antibiotic combination, EluPro offers physicians a solution designed for both efficacy and ease of use without compromise. “We are thrilled to introduce EluPro at HRS 2025 and give clinicians the opportunity to feel the difference biology makes,” said Dr. Kimberly Mulligan, GM and VP of Elutia’s Cardiovascular Division. “With its soft, conforming biomatrix and proven antibiotics, EluPro represents a meaningful step forward in CIED antibiotic envelope technology.” Elutia invites physicians and medical professionals to experience EluPro firsthand at booth #2418 at the San Diego Convention Center from April 25-27, 2025. Attendees interested in scheduling a meeting with Elutia during the conference may register through the HRS 2025 meeting portal here or contact ir@elutia.com. Those unable to attend can contact Elutia to speak with a representative and learn more about how EluPro is redefining CIED protection. About Elutia Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com. Forward Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Forward-looking statements contained in this press release include, without limitation, any statements we make regarding the potential for EluPro to represent a meaningful step forward in CIED antibiotic envelope technology. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: the risk that clinical research data may not match preclinical study data; our ability to successfully commercialize, market and sell our EluPro product; our ability to continue as a going concern; our ability to achieve or sustain profitability; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits and claims related to our recalled FiberCel and other viable bone matrix products and avoid a material adverse financial consequence from those lawsuits and claims; our ability to prevail in lawsuits and claims seeking indemnity, contribution and insurance coverage for FiberCel and other viable bone matrix product liabilities; the continued and future acceptance of our products by the medical community; our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings; our dependence on our commercial partners and independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; our ability to successfully realize the anticipated benefits of the sale of our Orthobiologics business; physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations could adversely affect our sales and profitability; our ability to obtain regulatory approval or other marketing authorizations by the FDA and comparable foreign authorities for our products and product candidates; our ability to obtain, maintain and adequately protect our intellectual property rights; and other important factors which can be found in the “Risk Factors” section of Elutia’s public filings with the Securities and Exchange Commission (“SEC”), including Elutia’s Annual Report on Form 10-K for the year ended December 31, 2024, as such factors may be updated from time to time in Elutia’s other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Elutia’s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investors:Matt SteinbergFINN Partnersmatt.steinberg@finnpartners.com This press release was published by a CLEAR® Verified individual.

Related News